Key facts
- Urania Therapeutics’s last known valuation is $5.4M.
- It has raised $8.1M; the latest was Seed Round ($1.4M) in Jul 2024.
- Notable investors include Bpifrance, Capital Grand Est, AdBio partners, Conectus, Institut de Génétique et de Biologie Moléculaire et Cellulaire — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Urania Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Urania Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Urania Therapeutics
Operator of a biopharmaceutical company intended to treat genetic diseases caused by mutations. The company's compounds induce the overcoming of premature stop codons during protein synthesis to allow the production of missing full-length protein for monogenic diseases such as Duchenne muscular dystrophy and cystic fibrosis, and cancers caused by nonsense mutations, enabling medical practitioners to restore production of functional proteins.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2015
- Employees
- 3
- Website
- uraniatx.com/
- Ownership
- Privately Held (backing)
Urania Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Urania Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Urania Therapeutics in its N-PORT filings yet. We sweep new filings monthly.